David A. Fost

Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial

Tim Harrison, Pascal Chanez, Francesco Menzella et al. · The Lancet Respiratory Medicine · 2020 · 175 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +15

Inhibition of methylprednisolone elimination in the presence of clarithromycin therapy

David A. Fost, Donald Y.M. Leung, Richard J. Martin et al. · Journal of Allergy and Clinical Immunology · 1999 · 123 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +6

Clarithromycin potentiates glucocorticoid responsiveness in patients with asthma: results of a pilot study

Joseph D. Spahn, David A. Fost, Ronina Covar et al. · Annals of Allergy Asthma & Immunology · 2001 · 63 citations

Pharmacy, Pharmacology, Pharmacotherapy +8

Severe Asthma Standard-of-Care Background Medication Reduction With Benralizumab: ANDHI in Practice Substudy

Renaud Louis, Tim Harrison, Pascal Chanez et al. · The Journal of Allergy and Clinical Immunology In Practice · 2023 · 24 citations · Full text

Pharmacy, Internal Medicine, Pharmacotherapy +13